Silver pharmacology: Past, present and questions for the future

Progress in Drug Research

Volumn 70, Issue , 2015, Pages 237-273

  Whitehouse, Michael W ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IONISED SILVER; SILVER; SILVER NANOPARTICLE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; METAL NANOPARTICLE;

ANTIBACTERIAL ACTIVITY; ARGYRIA; ARTICLE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; HISTORY OF MEDICINE; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; OXIDATION REDUCTION POTENTIAL; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STRUCTURE ANALYSIS; ANIMAL; CHEMISTRY;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; METAL NANOPARTICLES; SILVER;

EID: 84938511276     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0348-0927-6_7     Document Type: Article

References (119)

1. A short overview of colloidal nanosilver—production, properties, standards and bio-efficacy (Laroo 2013). [This is an open access article, distributed under the Creative Commons.]
2. An extensive review of ‘Nanobiosilver ‘and its uses in medicine with over 600 references (Eckhardt et al. 2013)
3. A comprehensive survey entitled “Nanosilver”, sponsored by the US Environmental Protection Agency, with over 500 references (Varner et al. 2010). [Ironically, this arm of the US government considers it to be ‘safe’, in contrast to the FDA which does not seem to agree with this conclusion.]
4. A valuable review of silver disposition, toxicity and utility for preventing infection, with over 160 references (Lansdown 2010) [This is also an open access article, distributed under the Creative Commons.]
5. A valuable bibliography particularly relating to the healing potential of silver colloids and electrically generated silver ions, with over 180 references (Flick 2009)
6. A short review covering silver’s history and silver nanoparticles as antimicrobials (Rai et al 2009)
7. A timely survey of silver nanotechnologies and the environment, with over 100 references (Luoma, 2008)
8. Challenging insight from Material Scientists about the complexities of aqueous nanosilver systems—including altered states of water and oxide ‘skins’ being formed around the nanoparticles (Roy et al 2007)
9. The phenomenon/problem of microbial silver resistance, reviewed by (Simon) Silver* (2003) (*Not a typographical error: this is the author’s surname.)
10. Two wider perspectives on selective toxicity (but not discussing silver) by the late Adrian Albert AO (1907–1989), the Australian National University, Canberra (Albert 1979, 1987)
11. Abraham GE, Himmel PB (1997) Management of rheumatoid arthritis: rationale for the use of colloidal metallic gold. J Nutr Environ Med 7:295–305
12. Adlof RO, Emken EA (1985) The isolation of omega-3 polyunsaturated fatty acids and methyl esters of fish oils by silver resin chromatography. J Oil Fat Ind 62:1592–1595
13. Albert A (1979) Selective toxicity: the physico-chemical basis of therapy, 6th edn. Chapman & Hall, London 662 pp
14. Albert A (1987) Xeniobiosis: foods, drugs, and poisons in the human body. Chapman and Hall, London 367 pp
15. Angell M (2004) The truth about the drug companies. How they deceived us and what to do about it. Random House, New York, 304 pp
16. Antelman MS (1997) Methods of curing AIDS with tetra-silver tetroxide molecular crystal devices. US Patent 5,676,977 (Oct. 14, 1997. C1.424/618)
17. Arner ESJ, Nakamura H, Sasada T, Yodoi J (2001) Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase and glutaredoxin by cisdiamminedichloroplatinum (II) and its major metabolite. Free Radical Biol Med 31:1170–1178
18. AshaRani PV, Mun GLK, Hande MP, Valiyaveettil S (2009) Cytotoxicity and genotoicity of silver nanoparticles in human cells. ACS Nano 3:279–290
19. Becker AJ, Becker RO, Flick AB (1998) Iontophoregic system for stimulation of tissue healing and regeneration. US Patent 5814094, 27 Sept 1998
20. Becker RO, Selden G (1985) The body electric. Electromagnetism and the fountain of life. Harper, New York, 364 pp. [especially Chapter 8, “The silver wand”, pp 163–180 and the Postscript “Political Science” pp 330–348]
21. Berners-Price SJ, Filipovska A (2011) Gold compounds as therapeutic agents for human diseases. Metallomics 3:863–873
22. Blindauer C (2011) Bacterial metallothioneins: past, present and questions for the future. J Biol Inorg Chem 16:1011–1024
23. Blindauer C (2014) personal communication
24. Bone K, Mills S (2013) Principles and practise of phytotherapy. Modern herbal medicine. Elsevier, Edinburgh, 1051 pp
25. Brown C, Bushell G, Whitehouse MW, Agrawal DS, Tupe KM, Paknakar KM, Tiekink ERT (2007) Nanogold pharmaceutics II Characterisation of the gold in Swarma Bhasma, a microparticulate used in Indian traditional medicine. Gold Bull 40:245–250
26. Brown CL, Whitehouse MW, Tiekink ERT, Bushell GR (2008) Colloidal metallic gold is not bio-inert. Inflammopharmacol. 167:133–137
27. Browne J. (2013) Silver In: Seven elements that have changed the world. London. Weidenfeldt & Nicolson, pp 105–125.
28. Browning E (1968) Silver in toxicity of industrial metals, 2nd edn. Butterworth, London, pp. 296–301
29. Brust M, Walker M, Bethell D, Schiffrin DJ, Whyman R (1994) Synthesis of thiol-derivatised gold nanoparticles in a two-phase liquid-liquid system. J Chem Soc Chem Commun 801–802
30. Burcham P (2010) Nanotoxicology: a primer for chemists. Chem Aust 77:18–22
31. Chappell JB, Greville GD (1954) Effect of silver ions on mitochondrial adenosine triphosphatase. Nature 174:930–931
32. Chaw KC, Manimaran M, Tay FEH (2005) Role of silver in destabilisation of intermolecular adhesion forces in Streptococcus epidermis biofilms. Antimicrob Agents Chemotherap 49:4853–4859
33. Cialla D, Bohme R, Theil F, Weber K, Schmitt M, Popp J (2012) Surface-enhanced Raman spectroscopy (SERS): progress and trends. Anal Bioanal Chem 403:27–54
34. Cock I, Mohanty S, White A, Whitehouse M (2012) Colloidal silver (CS) as an antiseptic: two opposing viewpoints. Pharmacog Comm 2:47–56
35. Costigan P, Ellis KJ (1980) Retention of copper oxide needles in cattle. Proc Aust Soc Animal Prod 6:637–642
36. Czoik R, Heintz A, John E, Marczak W (2008) Complexes of silver with histidine and imidazole investigated by the calorimetric and potentiometric methods. Acta Phys Pol, A 14:A52–A56
37. Demling RH, DeSanti L (2002) The rate of re-epithelialization across masked skin grafts is increased with exposure to silver. Burns 28:264–266
38. Dibrov P, Dzioba J, Gosink KK, Hase C (2002) Chemiosmotic mechanism of antimicrobial activity of Ag+ in Vibrio cholera. Antimicrob Agents Chemotherap 46:2668–2670
39. Disaanayake DMBT, Faoagali J, Laroo H, Hancock G, Whitehouse M (2014) Efficacy of some colloidal silver preparations and silver salts against Proteus bacteria, one possible cause of rheumatoid arthritis. Inflammopharmacol 22:73–77
40. Ebringer A (2012) Rheumatoid arthritis and Proteus. Springer, London, 223 pp
41. Ebringer A (2013) Ankylosing spondylitis and Klebsiella. Springer, London 256 pp
42. Ebringer A (2015) Multiple sclerosis, mad cow disease and Acinetobacter. Springer, London, 200 pp
43. Eckhardt S, Brunetto PS, Gagnon J, Prieve M, Geise B, Fromm KM (2013) Nanobio Silver: its interactions with peptides and bacteria, and its uses in medicine. Chem Rev 113:4708–4754
44. Evans M (2013) Encounter with god. Scripture Union, Milton Keynes, p 90
45. Fischer P, Jansen M (1995) Electrochemical syntheses of binary silver oxides. Inorg Synth 30:50–55
46. Flick AB (2009) Silver colloid bibliography, 183 references reproduced on the website “The Bigger Picture and the Quest for Truth” under the heading re colloidal silver “Isn’t it time the FDA went and ……?” http://www.911forum.org.uk/board/viewtopic.php?p=134716&sid=aecf964695bebd62b053876d0f5bb877 Retrieved 4 April 2014
47. Forbes G (1911) The solubility of silver chloride in chloride solutions and the existence of complex argentichloride ions. J Am Chem Soc 33:1737–1946
48. Forbes GS, Cole HI (1921) The solubility of silver chloride in dilute chloride solutions and the existence of complex argentichloride ions. II. J Am Chem Soc 43:2492–2497
49. Frausto da Silva JJR, Williams RJP (1991) The biological chemistry of the elements. Clarendon Press, Oxford 561 pp
50. Frens G, Overboek G (1969) Carey Lea’s colloidal silver. Kolloid-Zeitschrift und Zeitschrift für Polymere 223:922–929
51. Gibbs RJ (1999) Silver-colloids—do they work? http://www.silver-colloids.com. Accessed 8 April 2014
52. Gmelin M (1971) Silber In: Gmelin’s Handbuch der Anorganische Chemie, 8 Aulflage Nr 6. Verlag Chemie, Weinheim
53. Goldacre B (2012) Bad pharma: how drug companies mislead doctors and harm patients. Faber & Faber, London, 448 pp
54. Graham GG, Whitehouse MW, Bushell GR (2008) Aurocyanide, dicyanoaurate (I), a pharmacologically active metabolite of medicinal gold complexes. Inflammopharmacol. 16:126–132
55. Hancock GL (2011) Colloidal metallic silver, 2nd edn. Kalaya Publications, Kalbar. Accessed http://www.kalayaproducts.com.au]
56. Harper N (1958) Drug latentiation. J Med Chem 1: 467–500
57. Higginbottom J (1826) An essay on the application of the lunar caustic: in the cure of certain wounds and ulcers. Longman Rees Orme Brown & Green, London, 147 pp. (Kessinger Publishing: http://www.kessinger.net)
58. Hill WR, Pillsbury DM (1939) Argyria. The pharmacology of silver. Williams & Wilkins Co, Baltimore, 172 pp
59. Huang YF, Zhang M, Zhao LB, Feng JM, Wu DY, Ren B, Tian ZQ (2014) Activation of oxygen on gold and silver nanoparticles assisted by surface plasmon resonances. Angew Chem Int Ed Engl 53:2353–2357
60. Jefferson W (2003) Colloidal silver today. The all-natural wide-spectrum germ killer. Healthy Living Publications, Summertown, 63 pp
61. Jocelyn P (1972) Biochemistry of the SH group. Academic Press, London
62. Kalishwaralal K1, Barathmanikanth S, Pandian SR, Deepak V, Gurdinathan S (2010) Silver nanoparticles impede the biofilm formation of Pseudomonas aeruginosa and Streptococcus epidermis. Colloid Surf B Biointerfaces 79:340-344
63. Kean WF, Kean IR (2008) Clinical pharmacology of gold. Inflammopharmacol. 16:112–125
64. Kittler S, Greulich C, Diendorf J, Koller M, Epple M (2010) Toxicity of silver nanoparticles increases because of slow dissolution under release of silver ions. Chem Mater 22:4548–4554
65. Kornberg A, Pricer WE (1953) Isolation of diphosphopyridine nucleotide. Biochem Prep (ed. EE Snell) 3:20–24
66. Lansdown ABG (2010) A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices. Adv Pharmacol Sci. doi:10.1155/2010/910686
67. Laroo H (2013) Colloidal nanosilver—its production, methods, properties, standards and its bio-efficacy as an inorganic antibiotic. J Phys Chem Biophys 3(5):100130
68. Lau GW, Hassett DJ, Ran H, Kong F (2004) The role of pyocyanin in Pseudomonas aeruginosa infection. Trends Mol Med 10:599–606
69. Legke MF, Ravel B, Fleet ME, Wanger G, Gordon RA, Southam G (2006) Mechanisms of gold bioaccumulation by filamentous cyanobacteria from gold (III)-chloride complex. Environ Sci Technol 40:6304–6309
70. Legke MF, Fleet ME, Southam G (2007) Biosynthesis of silver nanoparticles by filamentous cyanobacteria from a silver (I) nitrate complex. Langmuir 23:2694–2699
71. Li L, Zhu Y-J (2006) High chemical reactivity of silver nanoparticles towards hydrochloric acid. J Col Interface Sci 303:415–418
72. Li P, Li J, Wu C, Wu Q, Li J (2005) Synergistic antibacterial effects of β-lactam antibiotic combined with silver nanoparticles. Nanotechnol 16:1912–1917
73. Liu J, Sunshine DA, Shervani S, Hurt RH (2010) Controlled release of biologically active silver from nanosilver surfaces. ACS Nano 4:6903–6913
74. Liu J, Pennell KG, Hurt RH (2011) Kinetics and mechanism of nanosilver oxysulfidation. Environ Sci Technol. doi:10.1021es2015539s
75. Loewenstein W, Fee K (1928) Uber kollargolbehandlung des chronischen gelenkrheumatismus. Klin Woch (Berlin) 39:1860–1864
76. Luoma SN (2008) Silver nanotechnologies and the environment: old problems or new challenges. Project on emerging technologies. (Pen) 15. Woodrow Wilson International Centre for Scholars, Washington DC
77. Maass GJ (2014) Dietary supplement silver nanoparticles: no threat to the environment. Pharmacog Comm
78. Mack D, Davies AP, Harris LG, Knobloch JKM, Rohde H (2009) Staphylococcus epidermidis biofilms: functional molecules, relation to virulence, and vaccine potential. Top Curr Chem 288:157–182
79. Madiera JM, Gibson DL, Kean WF, Klegeris A (2012) The biological activity of auranofin. Inflammopharmacol. 20:297–306
80. McMillan JA (1962) Higher oxidation state of silver. Chem Revs. 62:65–80
81. Mellor JW (1923) Comprehensive treatise on inorganic and physical chemistry, vol III. Longman Green, London, pp 295–490
82. Mitchell P (1966) Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. Biol Revs 41:445–502
83. Nesbitt RU Jr, Sandmann BJ (1977) Solubility studies of silver sulfadiazine. J Pharm Sci. 66:519–522
84. Nesbitt RU Jr, Sandmann BJ (1978) Solubility studies of silver sulfadiazine. J Pharm Sci 67:1012–1017
85. Omatu Y, Folan M, Shaw M, Messer RL, Lockwood PE, Hobbs D et al (2006) Sublethal concentrations of diverse gold compounds inhibit cytosolic thioredoxin reductases (TrxR1). Toxicol In Vitro 20:882–890
86. Osborne OJ, Johnston BD, Moger J, Balousha M, Lead JR, Kudoh T, Tyler CR (2012) Effects of particle size and coating on nanoscale Ag and Ti02 exposure in zebrafish (Daniio rerio) embryos. Nanotoxicology 1743–5404. doi:10.3109/17435390.2012.737484
87. Perrin DD (1979) Stability constants of metal ion complexes. Organic ligands, 2nd edn. Pergamon Press, Oxford, pp 1263
88. Peskett H (2014) Commentary on proverbs (Holy Bible) in Encounter with God. Scripture Union, Milton Keynes, UK p. 108
89. Rai M, Yadav A, Gade A (2009) Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 27:76–83
90. Roy R, Hoover MR, Bhalla AS, Slawecki T, Dey S, Cao W et al (2007) Ultradilute Ag aquasols with extraordinary bactericidal properties: role of the system Ag-0-H2O. Mater Res Innov 11:3–18
91. Ruden S, Hilpert K, Berditsch M, Wadhwani P, Ulrich AS (2009) Synergistic interactions between silver nanoparticles and membrane-permeabilising antimicrobial peptides. Antimicrob Agents Chem Ther 53:3538–3540
92. Shahverdi AR, Minacian S, Shahverdi HR, Jamalifar H, Lohi A-A (2007) Rapid synthesis of silver nanoparticles using culture supernatants of Enterobacteria: a novel biological approach. Process Biochem 42:919–923
93. Shaw CF III (1999) Gold-based therapeutic agents. Chem Rev 99:2589–2600
94. Shukla S, Sastry M (2009) Probing differential Ag+-nucleobase interactions with isothermal titration calorimetry (IT): toward patterned DNA metallization. Nanoscale 1:122–127
95. Silver S (2003) Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol Rev 27:341–353
96. Simpson WJ, Hewlett RT (1914) Experiments on the germicidal action of colloidal silver. Lancet 184:1359
97. Spadaro JA, Berger TJ, Barranco SD, Chapin SE, Becker RO (1974) Antibacterial effects of silver electrodes with weak direct current. AntimicrobAgents Chem Ther 6:637–642
98. Stahl P (ed) (1965) Thin layer chromatography., A laboratory handbook Springer, Berlin, pp 178–179
99. Stillman MJ, Presta A, Gui Z, Jiang DT (1994) Spectroscopy of copper, silver and gold— metallothioneins. Met-Based Drugs 1:375–394
100. Stwertka A (2012) A guide to the elements, 3rd edn. Oxford University Press, New York, pp 127–129
101. Suresh AK, Pelletier DA, Wang W, Moon J-W, G B, Mortensen NP et al (2010) Silver nanocrystallites: biofabrication using Shewanella oneidensis, and an evaluation of their comparative toxicity on Gram-negative and Gram-positive bacteria. Environ Sci Technol. 44:5210–5215
102. Suzuki Y, Yoshimaru T, Matsui T, Ra C (2002) Silver activates calcium signals in rat basophilic leukemia-2H3 mast cells. J Immunol 169:3954–3962
103. Sweet JE, Wilmer HP (1919) A treatment for trench fever. Lancet 252–254
104. Thompson NR (1973) Silver. In: Bailor JC, Emeleus HJ, Nyholm R, Trotman-Dickenson AF (eds) Comprehensive Inorganic Chemistry. Pergamon Press, Oxford, pp 79–128 (with 352 refs.)
105. Tiekink ERT (2008) Anti-cancer potential of gold complexes. Inflammopharmacol. 16:138–142
106. Tudela D (2008) Silver (II) oxide or silver (I, III) oxide? J Chem Educ 85:863–865
107. Varner K, El-Badaway A, Feldhake D, Venkatapathy R (2010) State of the science literature review: everything nanosilver and more. US Environmental Protetion Agency, Washington DC, 363 pp
108. Vasak M (2011) Metallothioneins: chemical and biological challenges. J Biol Inorg Chem 16:975–976 (An introduction to several mini reviews, pp 977–1134)
109. Venugopal B, Luckey TD (1978) Silver (Ag). In: Metal toxicity in mammals, vol 2. Chemical toxicity of metals and metalloids. Plenum Press, New York, pp 32–36
110. Walker WR, Beveridge SJ, Whitehouse MW (1980) Anti-inflammatory activity of a dermally applied copper salicylate preparation (Alcusal). Agents Actions 10:38–47
111. Walker WR, Keats DM (1976) An investigation of the therapeutic value of the ‘copper bracelet’. Agents Actions 6:454–459
112. Warheit DB, Sayes CM, Reed KL, Swain A (2008) How meaningful are the results of nanotoxicity studies in the absence of adequate material characterisation? Toxicol Sci 191:183–185
113. Webb JL (1966) Enzyme and metabolic inhibitors, vols III and V. Academic Press, New York Weil A (1996) Materia-medica. In: Health and healing. Warner Books, London, Chap. 9, pp. 96–111
114. Whitehouse MW (2009) Therapeutic gold: is it due for a comeback? Inflammopharmacology 16:107–109
115. Whitehouse MW, Butters DE (2014) Paracetamol (acetaminophen): a blessing or a hidden curse. Inflammopharmacology 22:63–65
116. Whitehouse M, Butters D, Vernon-Roberts B (2013) Conditional pharmacology/toxicology V: ambivalent effects of thiocyanate upon the development and the inhibition of experimental arthritis in rats by aurothiomalate (Myocrysin®) and metallic silver. 21:291–300
117. Whitehouse MW, Leader JE (1966) Uncoupling of oxidative phosporylation and inhibition of a thiol enzyme (papain) by some cyclic Beta-diones and ninhydrin. Biochem Pharmacol 16:537–551
118. Whitehouse MW, Walker WR (1978) Copper and inflammation. Agents Actions 8:85–90
119. Xiu Z, Zhang Q, Puppala HL, Colvin VL, Alvarez PJJ (2012) Negligible particle-specific antibacterial activity of silver nanoparticles. Nano Lett. 12:4271–4275